Facebook
X
LinkedIn
ForwardAnnual Review Course Webcast (2025)
Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast Only option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
For the ABU Qualifying (Part 1) Examination, residents need to possess basic working urologic knowledge and an understanding of how to utilize current American Urological Association practice guidelines. There exists variability in how prepared residents are for the Exam, indicating a need for further education. To fulfill this need, the AUA developed this course to disseminate current urologic knowledge and best practices to successfully prepare residents for the ABU examination. This course is also of interest to practicing urologists as well as others, including allied health professionals, looking for a thorough review of basic urologic topics.
Webcasts will be available to view on Wednesday, June 11, 2025.
Registration Fees
Membership Category | Registration Fee |
|---|---|
| Member | $1005 |
| Non-Member | $1255 |
| Member Resident/Allied | $555 |
| Non-Member Resident/Allied | $695 |
Target Audience
- Residents
- Urologists
Learning Objectives
After participation in this CME activity, participants will be able to:
- Demonstrate core knowledge of urology necessary for American Board of Urology (ABU) Qualifying (Part 1).
- Employ basic, generally accepted urological practices for effective, high-quality patient care.
- Utilize AUA Guidelines for appropriate patient evaluation and management.
Annual Review Course
June 6 - 8, 2025
Houston, TX
Scientific Program
Friday, June 6, 2025 | |
|---|---|
| 6:30 – 7:15 a.m. | Registration/Breakfast |
| 7:15 – 7:20 a.m. | Welcome Message Michael Coburn, MD, FACS Chair of Urology, Baylor |
| 7:20 – 7:30 a.m. | Introduction Howard B. Goldman, MD, FACS and Kristen R. Scarpato, MD, MPH |
| ANATOMY AND EMBRYOLOGY | |
| 7:30 – 9:15 a.m. | Applied Anatomy Embryology Howard B. Goldman, MD, FACS |
| 9:15 – 9:30 a.m. | Break |
| PEDIATRIC UROLOGY | |
| 9:30 – 10:15 a.m. | Congenital Urinary Tract Abnormalities |
| 10:15 – 11:00 a.m. | Pediatric Urinary Incontinence and Bladder Disorders Voiding Dysfunction and Neurogenic Bladder Developmental Anomalies of the Bladder Urinary Tract Infection and Secondary Reflux Management of Neurogenic and Non-Neurogenic Bladder Pediatric Metabolic Stones Diana Bowen, MD |
| 11:00 – 11:10 a.m. | Break |
| 11:10 – 11:40 a.m. | Disorders of the Genitalia/Scrotum Disorders of Sexual Differentiation Hypospadias Undescended Testicle Bruce J. Schlomer, MD |
| 11:40 a.m. – 12:10 p.m. | Pediatric Urological Oncology Wilms’ Tumor and Other Renal Tumors Rhabdomyosarcoma Neuroblastoma Testis Tumors Diana Bowen, MD |
| 12:10 – 12:40 p.m. | Pediatric Review Questions Diana Bowen, MD & Bruce J. Schlomer, MD |
| 12:40 – 1:45 p.m. | Lunch* |
| RENAL MEDICINE | |
| 1:45 – 2:30 p.m. | Renal Physiology (including Fluid and Electrolytes) Renal Transplant Renal Vascular Disease Nicholas G. Cowan, MD |
| ADRENDAL | |
| 2:30 p.m. – 3:15 p.m. | Epidemiology, Diagnosis and Imaging (including Cushings, Hyperaldosteronism, Pheochromocytoma, Cancer and the Incidentally Found Adrenal Mass) Management(including Pheochromocytoma, Cancer, Hyperaldosteronism, Incidentaloma and Metastatic Disease) Wesley Mayer, MD |
| 3:15 – 3:30 p.m. | Break |
| UROLITHIASIS | |
| 3:30 – 5:00 p.m. | Epidemiology, Pathophysiology Evaluation and Medical Management Surgical Management of Stone Disease Karen Stern, MD |
| 5:00 p.m. | Meeting Adjourns |
Saturday, June 7, 2025 | |
| 6:30 – 7:15 a.m. | Breakfast |
| LAPAROSCOPY | |
| 7:15 – 7:45 a.m. | Physiology and Complications Wesley Mayer, MD |
| BLADDER CANCER | |
| 7:45 – 8:30 a.m. | Epidemiology, Anatomy, Diagnosis and Imaging Treatment of NMIBC/Superficial Disease Management Kristen R. Scarpato, MD, MPH |
| 8:30 – 9:30 a.m. | Staging and Risk Stratification of Muscle Invasive Bladder Cancer Multidisciplinary Treatment including Radical Cystectomy, Lymphadenectomy, Peri-Operative Chemotherapy and Chemoradiation Therapy Metabolic Derangements that Occur with Diversions Other Bladder Sparing Treatments Treatment of Metastatic Disease Max R. Kates, MD |
| 9:30 – 9:45 a.m. | Break |
| 9:45 – 10:00 a.m. | Bladder Cancer Review Questions Kristen R. Scarpato, MD, MPH & Max R. Kates, MD |
| RENAL AND URETHRAL TUMORS | |
| 10:00 – 11:25 a.m. | Epidemiology, Anatomy, Diagnosis and Imaging (Including Evaluation of Renal Masses) Treatment of Localized Disease (including Role of Partial Nephrectomy) Treatment of Metastatic Disease Transitional Cell Carcinoma Robert G. Uzzo, MD, MBA, FACS |
| 11:25 – 11:35 a.m. | Break |
| TESTICULAR TUMORS | |
| 11:35 a.m. – 12:35 p.m. | Epidemiology, Diagnosis, Staging and Imaging (including the Role of Markers and CIS) Treatment of Seminoma Treatment of Non-Seminomatous Germ Cell Tumors (including Controversy Regarding Stage A Management, Risk Factors for Recurrence, Algorithms for Stages A,B, and C) Timothy A. Masterson, MD |
| 12:35 – 1:35 p.m. | Lunch* |
| PENILE AND URETHRAL CANCER | |
| 1:35 – 2:20 p.m. | Epidemiology Diagnosis and Staging Imaging and Treatment Robert G. Uzzo, MD, MBA, FACS |
| PROSTATE CANCER | |
| 2:20 – 3:35 p.m. | Diagnosis and Screen, Staging, Imaging (including PSA Screening Controversies) Treatment of Localized Cancer (U.S. Stages A and B), Watchful Waiting, Radiation, Interstitial Irradiation, Surgery, Cryosurgery and Hormonal Therapy Treatment of Advanced Cancer (U.S. Stages C and D) and Treatment of Radiation Failure DVT Prophylaxis Kristen R. Scarpato, MD, MPH |
| 3:35 – 3:50 p.m. | Break |
| TRAUMA AND RECONSTRUCTION | |
| 3:50 – 5:05 p.m. | Renal and Ureteral Trauma and Reconstruction Bladder and Urethral Trauma and Reconstruction Genital Trauma: Evaluation and Management Surgical Management of Male Incontinence Jay Simhan, MD, FACS |
| 5:05 p.m. | Meeting Adjourns |
Sunday, June 8, 2024 | |
| 6:30 – 7:15 a.m. | Breakfast |
| ERECTILE DYSFUNCTION | |
| 7:15 — 8:15 a.m. | Physiology of Erection, Pathophysiology of Erectile Dysfunction Evaluation and Management of Erectile Dysfunction Pathophysiology, Evaluation and Management of Priapism Pathophysiology, Evaluation and Management of Peyronie’s Disease Ryan P. Terlecki MD, FACS |
| GU RADIOLOGY | |
| 8:15 – 9:15 a.m. | Basics of MR, CT, US, VCUG Solid and Cystic Renal Masses (CT and MR) Transitional Cell Carcinoma Prostate MRI Adrenal Imaging Scrotal Imaging Retroperitoneal Tumors Radiation Basic Principles Vinay Prabhu, MD, MS |
| 9:15 – 9:30 a.m. | Break |
| FEMALE UROLOGY, FEMALE SEXUAL DYSFUNCTION, URODYNAMICS AND NEUROUROLOGY | |
| 9:30 – 10:45 a.m. | Overactive Bladder/Urgency Incontinence Stress Urinary Incontinence Pelvic Organ Prolapse Urethral Diverticulum Urinary Fistula Howard B. Goldman, MD, FACS |
| 10:45 – 10:55 a.m. | Break |
| 10:55 – 11:55 a.m. | Female Sexual Dysfunction Neurourology Anne P. Cameron, MD, FRCSC, FPMRS |
| 11:55 a.m. – 12:30 p.m | Urodynamics Basics Tracing Review Anne P. Cameron, MD, FRCSC, FPMRS |
| 12:30 – 1:30 p.m. | Lunch |
| URINARY TRACT INFECTION | |
| 1:30 – 2:00 p.m. | Urinary Tract Infections Bilal Chugthai, MD |
| INTERSTITIAL CYSTITIS AND SEXUALLY TRANSMITTED DISEASES | |
| 2:00 – 2:30 p.m. | Interstitial Cystitis Sexually Transmitted Diseases (Gonorrhea, Chlamydia, AIDS and others) Anne P. Cameron, MD, FRCSC, FPMRS |
| BPH | |
| 2:30 – 3:15 p.m. | Evaluation Medical Management Surgical Management Bilal Chughtai, MD |
| 3:15 – 3:30 p.m. | Break |
| INFERTILITY | |
| 3:30 – 5:00 p.m. | Physiology and Pathophysiology of Male Reproduction Evaluation of the Infertile Male Treatment of the Infertile Male (Surgical and Non-surgical) Hypogonadism Testosterone Replacement Sarah C. Vij, MD |
| 5:00 p.m. | Meeting Adjourns |
*Friday and Saturday Lunch will include opportunities to participate in a wellness activity and/or Lunch with the Experts - both first come, first serve by sign up only
Education Council Disclosures
Education Council Disclosures.pdf
COI Review Work Group Disclosures
COI Review Workgroup Disclosures.pdf
FACULTY DISCLOSURES
For a full listing of all faculty disclosures, please visit Annual Review Course Faculty Disclosures and click on the "Faculty" tab.
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pre-test, viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 24.00 hours
Release Date: June, 2025
Expiration Date: June, 2028
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 24.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Price
AUA Members save 25%! For more information on membership benefits, visit www.AUAnet.org/Join.
Registration Fees
Membership Category | Registration Fee |
|---|---|
| Member | $1005 |
| Non-Member | $1255 |
| Member Resident/Allied | $555 |
| Non-Member Resident/Allied | $695 |
Webcasts will be available to view on Wednesday, June 11, 2025.
CANCELLATION POLICY
Live Course: An administrative fee of 15% is assessed if registration is cancelled up to six weeks prior to the course. If registration is cancelled four to six weeks from the course, the cancellation fee is 50% of the registration fee paid. No registration fees will be refunded less than four weeks prior to the course. In the event that the Live Course converts from live in-person to a live virtual course, all registrations will be converted to the live virtual course and no full refunds will be issued. The Cancellation Policy will apply. The AUA cannot be held responsible for other costs or expenses, including cancellation/change penalties assessed by airlines, travel agencies or hotels.
Webcast: Cancellations must be made no later than one week prior to the live course. Subscription fees will not be refunded after the cancellation period. Purchases after the live course date are not eligible for a refund.
Registration Transfer: Customers switching from an option of lesser value to a higher value will be required to pay the difference in cost between the two options. Switching to an option of lesser value from a higher value must be made no later than to six weeks prior to the course and will be subject to an administrative fee of 15% of the cost of the course from which they are transferring. Transfer of registration from a higher value option to an option of lesser value past six weeks prior to the course will not receive a refund.
Cancellations must be made in writing. Requests may be made via mail or fax to 410-689-3912. Questions? Call 1-800-908-9414 or email [email protected].
AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before May 16, 2025. If AUA Education & Research cancels this course, notification will be sent by May 23, 2025.